GenScript and Allozymes join forces for precision protein engineering

03 Aug 2021 --- GenScript Biotech Corporation is collaborating with Allozymes, a synthetic biology company that uses specific technologies to “unlock protein engineering potential.”

In this partnership, GenScript will provide the mutant libraries construction to Allozymes for its downstream applications across various industries, including pharmaceuticals, cosmetics and F&B applications.

GenScript’s business operations span over 100 countries and regions worldwide, with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland.

Precision technology
GenScript will leverage strong expertise in de novo gene synthesis capabilities. The semiconductor-based oligo synthesis technology offers precise control over each synthesized variant to achieve a diverse and fully covered mutant library with unbiased distribution, the company asserts.

This precise and rational approach can save valuable target screening time, speed up discovery workflow and reduce overall downstream expenses.

Together with Allozymes’s patented screening platform, this partnership is expected to achieve significant breakthroughs in protein engineering research.

“We are building the next-generation of protein engineering platform placed at the heart of Asia, Singapore. The partnership with GenScript will accelerate our path and move us forward to reach our goal faster,” says Dr. Peyman Salehian, CEO and co-founder of Allozymes.

GenScript will leverage strong expertise in de novo gene synthesis capabilities to offer precise control over each synthesized variant in this partnership.According to Dawn Lee, South East Asia sales director from GenScript, the company is committed to supporting its partners in developing the Singapore bio-industry.

“Since our Asia Pacific office establishment, we have provided tailored support to the local researchers and acquired new clients, and Allozymes is one of them. Our proprietary technologies in gene synthesis complement Allozymes’s patented platform to help researchers in synthetic biology development.”

Protein engineering in the spotlight
In the past few months, recreating proteins using specific technologies such as fermentation has been a trending topic.

Moreover, alternative protein companies have emerged to create sustainable methods to produce conventional animal-based protein to feed a growing population.

Spanish dairy specialist Pascual recently launched what is tipped as the first global incubation program for cellular agriculture technologies in the dairy industry. The program, Mylkcubator, is run by the group’s new Corporate Venture unit, Pascual Innoventures, which has been set up to support start-ups disrupting the milk value chain.

In other developments, Time-Travelling Milkman recently scaled up its plant-based fat ingredient for creamier, healthier dairy alternatives following new funding from Oost NL and SHIFT Invest.

In April, Those Vegan Cowboys discussed with FoodIngredientsFirst how they are developing plant-based casein by precision fermentation.

According to milk ingredients specialist Laïta Nutrition, dairy companies “must reinvent themselves.” The company recently highlighted its narrowing focus on plant-based ingredients.

Edited by Elizabeth Green

To contact our editorial team please email us at editorial@cnsmedia.com